Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Unlabelled: Emerging evidence has shown that pre-trained encoder transformer models can extract information from unstructured clinic note text but require manual annotation for supervised fine-tuning. Large, Generative Pre-trained Transformer (GPT) models may streamline this process. In this study, we explore GPTs in zero- and few-shot learning scenarios to analyze clinical health records. We prompt-engineered Llama2 13B to optimize performance in extracting seizure freedom from epilepsy clinic notes and compared it against zero-shot and fine-tuned Bio + ClinicalBERT (BERT) models. Our evaluation encompasses different prompting paradigms, including one-word answers, elaboration-based responses, prompts with date formatting instructions, and prompts with dates in context. We found promising median accuracy rates in seizure freedom classification for zero-shot GPTs: one-word-62%, elaboration-50%, prompts with formatted dates-62%, and prompts with dates in context-74%. These outperform the zero-shot BERT model (25%) but fall short of the fully fine-tuned BERT model (84%). Furthermore, in sparse contexts, such as notes from general neurologists, the best performing GPT (76%) surpasses the fine-tuned BERT model (67%) in extracting seizure freedom. This study demonstrates the potential of GPTs in extracting clinically relevant information from unstructured EHR text, offering insights into population trends in seizure management, drug effects, risk factors, and healthcare disparities. Moreover, GPTs exhibit superiority over task-specific models in contexts with the potential to include less precise descriptions of epilepsy and seizures, highlighting their versatility. Additionally, simple prompt engineering techniques enhance model accuracy, presenting a framework for leveraging EHR data with zero clinical annotation.

Supplementary Information: The online version contains supplementary material available at 10.1007/s41666-025-00198-5.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12290146PMC
http://dx.doi.org/10.1007/s41666-025-00198-5DOI Listing

Publication Analysis

Top Keywords

seizure freedom
12
bert model
12
extracting seizure
8
prompts dates
8
fine-tuned bert
8
seizure
5
zero-shot
4
zero-shot extraction
4
extraction seizure
4
seizure outcomes
4

Similar Publications

Intraoperative electrocorticography (ECoG) represents a crucial tool for improving seizure outcomes during epilepsy surgeries by assisting in localization of the epileptogenic zones. There is a shortage of information in the literature regarding single-center experiences and long-term outcomes after ECoG-guided surgeries. Data are particularly scarce from the Eastern Mediterranean Region.

View Article and Find Full Text PDF

Objective: Despite pharmacological advances in epilepsy treatment, one-third of patients remain pharmacoresistant and may require surgery. Despite extensive literature on epilepsy surgery, studies with follow-ups longer than 5 years are rare. Our goal was to analyze the outcomes of patients undergoing epilepsy surgery at our center, with a minimum follow-up of 15 years.

View Article and Find Full Text PDF

Background: To systematically evaluate the efficacy, safety, and tolerability of adjunctive lacosamide (LCM) in children and adolescents with drug-resistant epilepsy (DRE).

Methods: A systematic review and single-arm meta-analysis was conducted in accordance with PRISMA 2020 guidelines. MEDLINE, Embase, and Cochrane Library were searched up to April 2025.

View Article and Find Full Text PDF

Objective: Open resective surgery (ORS) has become the standard of care for focal drug-resistant epilepsy (DRE). However, minimally invasive surgical alternatives, such as laser interstitial thermal therapy (LITT), have also been shown to be safe and effective. A meta-analysis comparing both treatments is warranted to assess the benefits of each modality for focal DRE.

View Article and Find Full Text PDF

Epilepsy affects around 1% of the global population and often requires long-term treatment with antiseizure medications (ASMs). However, the current treatment strategy is based on clinical acumen and trial and error, resulting in only about 50% of patients remaining seizure-free for at least 12 months with first-line ASMs. Valproic acid (VPA) is a commonly prescribed first-line ASM, yet <50% of patients experience inadequate seizure control (ISC) or unacceptable adverse reactions (UARs), necessitating discontinuation.

View Article and Find Full Text PDF